Understanding Using Public Access Clinical Databases To Interpret Ngs Variants
If you are looking for information about Using Public Access Clinical Databases To Interpret Ngs Variants, you have come to the right place. In this webcast, Gabe Rudy, Vice President of Product Development, will showcase publicly available
Key Takeaways about Using Public Access Clinical Databases To Interpret Ngs Variants
- Interpretation
- Find out how to view analysis results
- Presented
- Albert Ferran finished his MSc in Genetic Anthropology in 2011 and worked as a research scientist at The University of Barcelona ...
- FDA has released 2 regualtory guidances regarding the
Detailed Analysis of Using Public Access Clinical Databases To Interpret Ngs Variants
Eunice Lee, Ph.D., Branch Chief, Division of Molecular Genetics and Pathology, OIR/CDRH/FDA. The This is a recording of the webinar from March 19, 2025, including: -
The video was recorded live during the SIB course “
We hope this detailed breakdown of Using Public Access Clinical Databases To Interpret Ngs Variants was helpful.